Company Overview of Visterra, Inc.
Visterra, Inc., a clinical-stage biopharmaceutical company, focuses on applying its Hierotope platform to identify unique disease targets and to design and engineer antibody-based therapies that are intended to be effective as a single-dose administration. Its lead product candidate is VIS410, a monoclonal antibody (mAb) that is in Phase IIa clinical trials for the treatment of hospitalized patients with influenza A. The company also develops VIS513, a mAb for the treatment of dengue. Its early-stage programs include antibody-based programs VIS-FLX for the prevention of influenza A in high-risk populations. Visterra, Inc. has collaboration and license agreements with Massachusetts Institute ...
One Kendall Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Visterra, Inc.
Chief Executive Officer, President and Director
Founder, Chairman of The Board, Chairman of Compensation Committee and Member of Audit Committee
Chief Financial Officer and Chief Operating Officer
General Counsel and Secretary
Compensation as of Fiscal Year 2015.
Visterra, Inc. Key Developments
Visterra, Inc. and Serum Institute of India Ltd. Enter into License Agreement for Development, Manufacture and Commercialization of VIS513
Sep 9 15
Visterra, Inc. and Serum Institute of India Ltd. announced that the companies have entered into a license agreement for the development, manufacture and commercialization of VIS513 in the Indian subcontinent countries. VIS513 is Visterra’s humanized monoclonal antibody that was designed to bind and potently neutralize all four serotypes of dengue virus and was engineered using Visterra’s innovative and proprietary HierotopeTM technology. Preclinical studies of VIS513 have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its continued development as a single administration for the treatment of dengue virus infection. Under the terms of the agreement, Serum Institute receives an exclusive license to VIS513 for the Indian subcontinent, including India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka. Serum Institute will pay Visterra a $5 million upfront payment, plus up to $34 million based on the achievement of certain development and commercial milestones. Once VIS513 is commercialized, Visterra will be eligible to receive tiered, double-digit royalties based on net sales in the licensed territories. Serum Institute will fund and be responsible for the clinical development of VIS513 in the licensed territories, including the filing of regulatory applications. The companies will establish a joint steering committee primarily to coordinate VIS513 development activities for the Indian subcontinent with the global development strategy. Serum Institute will be responsible for commercializing VIS513 in the licensed territories.
Visterra, Inc. Names John Weidenbruch as General Counsel and Secretary of the Board of Directors
Sep 2 15
Visterra, Inc. announced that it has appointed John Weidenbruch as General Counsel and Secretary of the Board of Directors. John Weidenbruch has more than two decades of legal affairs and policy experience in the biotechnology industry. Most recently Mr. Weidenbruch was at Biogen, Inc., since 2010 where he served as Vice President, Chief Global Commercial Counsel. Prior to joining Biogen, he was Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Idenix Pharmaceuticals, Inc., from 2006 to 2010. Prior to Idenix, Mr. Weidenbruch was General Counsel at Abraxis BioScience Inc. Previously, he spent more than ten years at Amgen, Inc., where he held positions of increasing responsibility in the legal and healthcare policy departments.
Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains
Aug 8 15
Visterra, Inc. announced that new preclinical results for VIS410, Visterra’s novel monoclonal antibody in development for the treatment of seasonal and pandemic influenza, were published online August 17, 2015 in the journal Proceedings of the National Academy of Sciences (Tharakaraman et al., 2015, PNAS, doi:10.1073/pnas.1502374112). In the paper titled 'A Broadly Neutralizing Human Monoclonal Antibody is Effective Against H7N9,' Visterra scientists and scientists at the Massachusetts Institute of Technology (MIT), University of Hong Kong, and Utah State University describe preclinical data demonstrating that VIS410 binds to a wide range of representative group 1 and group 2 influenza viruses, and protected mice challenged with the H3N2 and H7N9 virus. Additionally, the paper presents preclinical data that VIS410 demonstrated a synergistic effect with oseltamivir, an existing small molecule anti-viral drug. These data support the continued development of VIS410 by Visterra as a single administration treatment for seasonal and pandemic influenza A.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|